ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Follow-Up Questions
Who is the CEO of ProKidney Corp?
Dr. Bruce Culleton is the Chief Executive Officer of ProKidney Corp, joining the firm since 2023.
What is the price performance of PROK stock?
The current price of PROK is $3.14, it has increased 5.72% in the last trading day.
What are the primary business themes or industries for ProKidney Corp?
ProKidney Corp belongs to Biotechnology industry and the sector is Health Care
What is ProKidney Corp market cap?
ProKidney Corp's current market cap is $924.0M
Is ProKidney Corp a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for ProKidney Corp, including 5 strong buy, 4 buy, 4 hold, 1 sell, and 5 strong sell
